Respiratory Plus: Cipla Shapes Future In New Age Platforms, Devices, Diagnostics
Executive Summary
The next chapter of Cipla’s innovation journey goes beyond its core respiratory thrust to include new platforms spanning areas such as peptides, where it has seen its first major approval in the US and has multiple programs lined up. Devices and diagnostics are among the other avenues being explored as the Indian company seeks to bring more patients into the “funnel”.
You may also be interested in...
Trends Shaping India Pharma: Next-Gen Therapies, Adjacencies, LOE Strategies And More
The arrival of an indigenous CAR-T cell therapy, a shot at GLP-1s and Parkinson’s disease, strides into adjacencies and an “easy revenue stream” formula for products set to lose exclusivity are some of the striking developments seen playing out in India. Industry leaders, including Cipla’s CEO, share their views with Scrip on some of the key trends in the first instalment of this two-part roundup.
Indian ‘Lighthouses’ Deliver Gains Amid Price Erosion, Rising Input Costs
Senior executives from Dr Reddy’s and Cipla showcase the “step-change” in performance across cost, quality and delivery metrics at their ‘lighthouse’ manufacturing sites in India as industry tackles dwindling operating margins and evolving compliance requirements.
Cipla's Advair Generic Debut Is In Sight
Cipla believes it is “pretty close” to approval for its Advair generic in the US, while another product, generic Abraxane, stands delayed currently. Following the deal with Ethris, which is progressing inhaled mRNA-based therapies, the company signals interest in platforms such as CAR-T as well.